TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 LIST OF ASSUMPTIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING NUMBER OF CLINICAL TRIALS
4.2.2 STRONG HEALTHCARE INFRASTRUCTURE
4.3 RESTRAINTS
4.3.1 SHORTAGE OF SKILLED AND EXPERIENCED PROFESSIONALS
4.4 OPPORTUNITY
4.4.1 DIGITAL TRANSFORMATION IN CLINICAL TRIALS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 CUSTOMER ACQUISITION (PREPURCHASE QUERY)
5.1.2 SERVICE CUSTOMIZATION
5.1.3 CUSTOMER PURCHASE SUPPORT
5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON EUROPE CLINICAL TRIAL MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON PRICING
5.3.3 IMPACT ON KEY PLAYERS
6 PREMIUM INSIGHTS
6.1 NUMBER (#) OF CLINICAL STUDIES ARE CONDUCTED IN GERMANY AND AUSTRIA, 2022-23
6.2 OVERVIEW OF SERVICE PRICING AND AGREEMENTS
6.2.1 HOW ARE THE OFFERS CALCULATED BY HOURS OR BY ANOTHER KEY
6.3 SURVEY ANALYSIS ON “MOST IMPORTANT CRITERIA FOR CLIENTS TO COMMISSION A STUDY
7 EUROPE CLINICAL TRIALS MARKET, BY PHASE
7.1 OVERVIEW
7.2 AVERAGE REVENUE PER STUDY
7.3 PHASE I
7.4 PHASE II
7.4.1 PHASE IIA
7.4.2 PHASE IIB
7.5 PHASE III
7.6 PHASE IV
8 EUROPE CLINICAL TRIALS MARKET, BY STUDY DESIGN
8.1 OVERVIEW
8.2 OBSERVATIONAL
8.3 INTERVENTIONAL
8.4 EXPANDED ACCESS
9 EUROPE CLINICAL TRIALS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 PHARMACEUTICAL
9.2.1 NEUROLOGICAL
9.2.2 ONCOLOGY
9.2.3 CARDIOVASCULAR
9.2.4 INFECTIOUS DISEASES
9.2.5 OTHERS
9.3 MEDICAL DEVICES
9.4 NUTRITION
9.5 OTHERS
10 EUROPE CLINICAL TRIALS MARKET, BY SERVICE TYPE
10.1 OVERVIEW
10.2 PROTOCOL DESIGNING
10.3 SITE IDENTIFICATION
10.4 PATIENT RECRUITMENT
10.5 LABORATORY SERVICES
10.6 BIOANALYTICAL TESTING SERVICES
10.7 CLINICAL TRIAL DATA MANAGEMENT SERVICES
10.8 OTHERS
11 EUROPE CLINICAL TRIALS MARKET, BY END USER
11.1 OVERVIEW
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.3 MEDICAL DEVICE COMPANIES
11.4 ACADEMIC & RESEARCH INSTITUTES
11.5 NUTRACEUTICAL COMPANIES
12 EUROPE CLINICAL TRIALS MARKET, BY COUNTRY
12.1 OVERVIEW
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 UK
12.1.4 ITALY
12.1.5 SPAIN
12.1.6 AUSTRIA
12.1.7 REST OF EUROPE
13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 COMPETITIVE BENCHMARKING
13.3 MAJOR GROWTH STRATEGY IN THE EUROPE CLINICAL TRIALS MARKET
13.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE EUROPE CLINICAL TRIALS MARKET
13.5 KEY DEVELOPMENT ANALYSIS
13.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
13.6.1 SERVICE LAUNCH
13.6.2 MERGER/ACQUISITION
13.6.3 PARTNERSHIP/COLLABOARTION/AGREEMENT/EXPANSION/INVESTMENT
13.7 FINANCIAL MATRIX
13.7.1 SALES (USD MILLION), 2022
13.7.2 TURNOVER OF CROS WORLDWIDE, EUROPE-WIDE, AND GERMANY AND AUSTRIA
14.1 CHARLES RIVER LABORATORIES
14.1.1 COMPANY OVERVIEW
14.1.2 FINANCIAL OVERVIEW
14.1.3 SERVICES OFFERED
14.1.4 KEY DEVELOPMENTS
14.1.5 SWOT ANALYSIS
14.1.6 KEY STRATEGIES
14.2 PAREXEL INTERNATIONAL (MA) CORPORATION
14.2.1 COMPANY OVERVIEW
14.2.2 FINANCIAL OVERVIEW
14.2.3 SERVICES OFFERED
14.2.4 KEY DEVELOPMENTS
14.2.5 KEY STRATEGIES
14.3 ICON PLC
14.3.1 COMPANY OVERVIEW
14.3.2 FINANCIAL OVERVIEW
14.3.3 SERVICES OFFERED
14.3.4 KEY DEVELOPMENTS
14.3.5 SWOT ANALYSIS
14.3.6 KEY STRATEGIES
14.4 LABORATORY CORPORATION OF AMERICA HOLDINGS
14.4.1 COMPANY OVERVIEW
14.4.2 FINANCIAL OVERVIEW
14.4.3 SERVICES OFFERED
14.4.4 KEY DEVELOPMENTS
14.4.5 SWOT ANALYSIS
14.4.6 KEY STRATEGIES
14.5 PPD INC
14.5.1 COMPANY OVERVIEW
14.5.2 FINANCIAL OVERVIEW
14.5.3 SERVICES OFFERED
14.5.4 KEY DEVELOPMENTS
14.5.5 SWOT ANALYSIS
14.5.6 KEY STRATEGIES
14.6 SYNEOS HEALTH
14.6.1 COMPANY OVERVIEWS
14.6.2 FINANCIAL OVERVIEW
14.6.3 SERVICES OFFERED
14.6.4 KEY DEVELOPMENTS
14.6.5 KEY STRATEGIES
14.7 CTI CLINICAL TRIAL & CONSULTING
14.7.1 COMPANY OVERVIEW
14.7.2 FINANCIAL OVERVIEW
14.7.3 SERVICES OFFERED
14.7.4 KEY DEVELOPMENTS
14.7.5 KEY STRATEGIES
14.8 IQVIA
14.8.1 COMPANY OVERVIEW
14.8.2 FINANCIAL OVERVIEW
14.8.3 SERVICES OFFERED
14.8.4 KEY DEVELOPMENTS
14.8.5 SWOT ANALYSIS
14.8.6 KEY STRATEGIES
14.9 MEDPACE INC
14.9.1 COMPANY OVERVIEW
14.9.2 FINANCIAL OVERVIEW
14.9.3 SERVICES OFFERED
14.9.4 KEY DEVELOPMENTS
14.9.5 KEY STRATEGIES
14.10 ANTAEA MEDICAL SERVICES LTD.
14.10.1 COMPANY OVERVIEW
14.10.2 FINANCIAL ANALYSIS
14.10.3 SERVICES OFFERED
14.10.4 KEY DEVELOPMENTS
14.10.5 KEY STRATEGIES
15 APPENDIX
15.1 REFERENCES
15.2 RELATED REPORTS
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 NUMBER (#) OF CLINICAL STUDIES ARE CONDUCTED, 2022-2023
TABLE 3 EUROPE CLINICAL TRIALS MARKET, FOR PHASE, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 4 EUROPE CLINICAL TRIALS MARKET, FOR PHASE I, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 5 EUROPE CLINICAL TRIALS MARKET, FOR PHASE II, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 6 EUROPE CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION)
TABLE 7 EUROPE CLINICAL TRIALS MARKET, FOR PHASE IIA, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 8 EUROPE CLINICAL TRIALS MARKET, FOR PHASE IIB, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 9 EUROPE CLINICAL TRIALS MARKET, FOR PHASE III, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 10 EUROPE CLINICAL TRIALS MARKET, FOR PHASE III, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 11 EUROPE CLINICAL TRIALS MARKET, FOR STUDY DESIGN, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 12 EUROPE CLINICAL TRIALS MARKET, FOR OBSERVATIONAL, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 13 EUROPE CLINICAL TRIALS MARKET, FOR INTERVENTIONAL, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 14 EUROPE CLINICAL TRIALS MARKET, FOR EXPANDED ACCESS, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 15 EUROPE CLINICAL TRIALS MARKET, FOR APPLICATION, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 16 EUROPE CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 17 EUROPE CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION)
TABLE 18 EUROPE CLINICAL TRIALS MARKET, FOR NEUROLOGICAL, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 19 EUROPE CLINICAL TRIALS MARKET, FOR ONCOLOGY, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 20 EUROPE CLINICAL TRIALS MARKET, FOR CARDIOVASCULAR, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 21 EUROPE CLINICAL TRIALS MARKET, FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 22 EUROPE CLINICAL TRIALS MARKET, FOR OTHERS, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 23 EUROPE CLINICAL TRIALS MARKET, FOR MEDICAL DEVICES, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 24 EUROPE CLINICAL TRIALS MARKET, FOR NUTRITION, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 25 EUROPE CLINICAL TRIALS MARKET, FOR OTHERS, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 26 EUROPE CLINICAL TRIALS MARKET, FOR SERVICE TYPE, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 27 EUROPE CLINICAL TRIALS MARKET, FOR PROTOCOL DESIGNING, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 28 EUROPE CLINICAL TRIALS MARKET, FOR SITE IDENTIFICATION, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 29 EUROPE CLINICAL TRIALS MARKET, FOR PATIENT RECRUITMENT, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 30 EUROPE CLINICAL TRIALS MARKET, FOR LABORATORY SERVICES, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 31 EUROPE CLINICAL TRIALS MARKET, FOR BIOANALYTICAL TESTING SERVICES, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 32 EUROPE CLINICAL TRIALS MARKET, FOR CLINICAL TRIAL DATA MANAGEMENT SERVICES, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 33 EUROPE CLINICAL TRIALS MARKET, FOR OTHERS, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 34 EUROPE CLINICAL TRIALS MARKET, FOR END USER, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 35 EUROPE CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 36 EUROPE CLINICAL TRIALS MARKET, FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 37 EUROPE CLINICAL TRIALS MARKET, FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 38 EUROPE CLINICAL TRIALS MARKET, FOR NUTRACEUTICAL COMPANIES, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 39 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2030 (USD MILLION)
TABLE 40 GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION)
TABLE 41 GERMANY: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION)
TABLE 42 GERMANY: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION)
TABLE 43 GERMANY: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION)
TABLE 44 GERMANY: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION)
TABLE 45 GERMANY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION)
TABLE 46 GERMANY: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION)
TABLE 47 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION)
TABLE 48 FRANCE: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION)
TABLE 49 FRANCE: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION)
TABLE 50 FRANCE: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION)
TABLE 51 FRANCE: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION)
TABLE 52 FRANCE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION)
TABLE 53 FRANCE: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION)
TABLE 54 UK: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION)
TABLE 55 UK: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION)
TABLE 56 UK: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION)
TABLE 57 UK: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION)
TABLE 58 UK: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION)
TABLE 59 UK: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION)
TABLE 60 UK: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION)
TABLE 61 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION)
TABLE 62 ITALY: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION)
TABLE 63 ITALY: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION)
TABLE 64 ITALY: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION)
TABLE 65 ITALY: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION)
TABLE 66 ITALY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION)
TABLE 67 ITALY: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION)
TABLE 68 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION)
TABLE 69 SPAIN: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION)
TABLE 70 SPAIN: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION)
TABLE 71 SPAIN: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION)
TABLE 72 SPAIN: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION)
TABLE 73 SPAIN: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION)
TABLE 74 SPAIN: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION)
TABLE 75 AUSTRIA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION)
TABLE 76 AUSTRIA: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION)
TABLE 77 AUSTRIA: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION)
TABLE 78 AUSTRIA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION)
TABLE 79 AUSTRIA: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION)
TABLE 80 AUSTRIA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION)
TABLE 81 AUSTRIA: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION)
TABLE 82 REST OF EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2030 (USD MILLION)
TABLE 83 REST OF EUROPE: CLINICAL TRIALS MARKET, FOR PHASE II, BY TYPE, 2019–2030 (USD MILLION)
TABLE 84 REST OF EUROPE: CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019–2030 (USD MILLION)
TABLE 85 REST OF EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2030 (USD MILLION)
TABLE 86 REST OF EUROPE: CLINICAL TRIALS MARKET, FOR PHARMACEUTICAL, BY TYPE, 2019–2030 (USD MILLION)
TABLE 87 REST OF EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2030 (USD MILLION)
TABLE 88 REST OF EUROPE: CLINICAL TRIALS MARKET BY END USER, 2019–2030 (USD MILLION)
TABLE 89 MAJOR PLAYERS IN THE EUROPE CLINICAL TRIALS MARKET
TABLE 90 MOST ACTIVE PLAYER IN THE EUROPE CLINICAL TRIALS MARKET
TABLE 91 SERVICE LAUNCH
TABLE 92 MERGER/ACQUISITION
TABLE 93 PARTNERSHIP/COLLABOARTION/AGREEMENT/EXPANSION/INVESTMENT
TABLE 94 MARGINS FROM SERVICES OFFERED FOR CLINICAL STUDIES IN THE MEDICAL DEVICE AND PHARMACEUTICAL AREA, 2022-2023
TABLE 95 CHARLES RIVER LABORATORIES: SERVICES OFFERED
TABLE 96 PAREXEL INTERNATIONAL (MA) CORPORATION: SERVICES OFFERED
TABLE 97 ICON PLC: SERVICES OFFERED
TABLE 98 ICON PLC: KEY DEVELOPMENTS
TABLE 99 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES OFFERED
TABLE 100 PPD INC: SERVICES OFFERED
TABLE 101 PPD INC: KEY DEVELOPMENTS
TABLE 102 SYNEOS HEALTH: SERVICES OFFERED
TABLE 103 SYNEOS HEALTH: KEY DEVELOPMENTS
TABLE 104 CTI CLINICAL TRIAL & CONSULTING: SERVICES OFFERED
TABLE 105 IQVIA: SERVICES OFFERED
TABLE 106 MEDPACE INC: SERVICES OFFERED
TABLE 107 ANTAEA MEDICAL SERVICES LTD: SERVICES OFFERED
LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 EUROPE CLINICAL TRIALS MARKET STRUCTURE
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: EUROPE CLINICAL TRIALS MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: EUROPE CLINICAL TRIALS MARKET
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: EUROPE CLINICAL TRIALS MARKET
FIGURE 9 EUROPE CLINICAL TRIALS MARKET, PHASE SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION)
FIGURE 10 EUROPE CLINICAL TRIALS MARKET, FOR PHASE, BY COUNTRY, 2022 & 2030 (USD MILLION)
FIGURE 11 EUROPE CLINICAL TRIALS MARKET SHARE (%), FOR PHASE, BY COUNTRY, 2022
FIGURE 12 EUROPE CLINICAL TRIALS MARKET, STUDY DESIGN SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION)
FIGURE 13 EUROPE CLINICAL TRIALS MARKET, FOR STUDY DESIGN, BY COUNTRY, 2022 & 2030 (USD MILLION)
FIGURE 14 EUROPE CLINICAL TRIALS MARKET SHARE (%), FOR STUDY DESIGN, BY COUNTRY, 2022
FIGURE 15 EUROPE CLINICAL TRIALS MARKET, APPLICATION SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION)
FIGURE 16 EUROPE CLINICAL TRIALS MARKET, FOR APPLICATION, BY COUNTRY, 2022 & 2030 (USD MILLION)
FIGURE 17 EUROPE CLINICAL TRIALS MARKET SHARE (%), FOR APPLICATION, BY COUNTRY, 2022
FIGURE 18 EUROPE CLINICAL TRIALS MARKET, SERVICE TYPE SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION)
FIGURE 19 EUROPE CLINICAL TRIALS MARKET, FOR SERVICE TYPE, BY COUNTRY, 2022 & 2030 (USD MILLION)
FIGURE 20 EUROPE CLINICAL TRIALS MARKET SHARE (%), FOR SERVICE TYPE, BY COUNTRY, 2022
FIGURE 21 EUROPE CLINICAL TRIALS MARKET, END USER SEGMENT ATTRACTIVENESS, 2019-2030 (USD MILLION)
FIGURE 22 EUROPE CLINICAL TRIALS MARKET, FOR END USER, BY COUNTRY, 2022 & 2030 (USD MILLION)
FIGURE 23 EUROPE CLINICAL TRIALS MARKET SHARE (%), FOR END USER, BY COUNTRY, 2022
FIGURE 24 EUROPE MARKET ANALYSIS: CLINICAL TRIALS MARKET, 2019-2030 (USD MILLION)
FIGURE 25 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY, 2022 & 2030 (USD MILLION)
FIGURE 26 EUROPE: CLINICAL TRIALS MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 27 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 28 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE EUROPE CLINICAL TRIALS MARKET
FIGURE 29 EUROPE FILL FINISH MANUFACTURING MARKET: COMPETITIVE LANDSCAPE
FIGURE 30 SALES 2022
FIGURE 31 CHARLES RIVER LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 CHARLES RIVER LABORATORIES: SWOT ANALYSIS
FIGURE 33 ICON PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 ICON PLC: SWOT ANALYSIS
FIGURE 35 LABORATORY CORPORATION OF AMERICA HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS
FIGURE 37 PPD INC: SWOT ANALYSIS
FIGURE 38 SYNEOS HEALTH: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 IQVIA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 IQVIA: SWOT ANALYSIS
FIGURE 41 MEDPACE INC: FINANCIAL OVERVIEW
